Currently, the analyst consensus on Vertex Pharmaceuticals is a Moderate Buy with an average price target of $392.58, which is a 3.1% upside from current levels. In a report issued on November 2, Canaccord Genuity also maintained a Hold rating on the stock with a $315.00...